Key metrics snapshot (QQ2 2024, CNY):
- Revenue: 823,746,000
- Cost of Revenue: 15,060,000
- Gross Profit: 808,688,000
- Gross Margin: 0.9817 (98.17%)
- R&D Expenses: 444,080,000
- SG&A + Selling Expenses: 176,626,000
- Operating Expenses: 620,704,000
- Operating Income: 187,984,000
- Operating Margin: 0.2282 (22.82%)
- EBITDA: 229,586,000
- EBITDA Margin: 0.2787 (27.87%)
- Other Income/Expense: -25,089,000
- Income Before Tax: 162,895,000
- Income Tax Expense: 69,000
- Net Income: 163,002,000
- Net Margin: 0.1979 (19.78%)
- EPS (Basic): 2.24; EPS (Diluted): 2.20
- Weighted Avg Shares (basic): 74,091,250; (diluted): 74,006,000
- Net Cash From Operating Activities: -354,390,000
- Free Cash Flow: -370,916,000
- Cash and Equivalents: ~1,100,314,000
- Total Assets: 3,107,070,000
- Total Liabilities: 2,330,631,000
- Total Stockholders’ Equity: 766,399,000
- Total Debt: 1,700,095,000; Net Debt: 599,781,000
- Current Ratio (approximate): ~1.84x (based on current assets 1,963,839,000 and current liabilities 1,065,350,000)
Note: The company exhibits strong gross margins and positive net income in the quarter, but operating cash flow remains negative due to high R&D investment and notable non-cash adjustments. Management commentary (where available) would be critical to interpret pipeline progress against cash burn and funding runway.